NephroGenex to Participate in Two Healthcare Conferences in June

RALEIGH, N.C.--()--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with members of the investment community at two healthcare conferences in June.

2015 BIO International Convention:

  • Location: Pennsylvania Convention Center, Philadelphia, PA
  • Presentation Date: Tuesday, June 16
  • Presentation Time: 3:15 p.m. EDT

JMP Securities Life Sciences Conference:

  • Location: St. Regis Hotel, New York, NY
  • Presentation Date: Tuesday, June 23
  • Presentation Time: 12:00 p.m. EDT

About NephroGenex, Inc.

NephroGenex (Nasdaq:NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

Cautionary Note on Forward-Looking Statements

Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under "Part I—Item 1A—Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission ("SEC") on March 24, 2015 and under “Part II—Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed with the SEC on May 13, 2015, as well as in other filings that we may make with the SEC in the future.

Contacts

Investors:
The Trout Group
Michael Levitan, 646-378-2920
mlevitan@troutgroup.com
or
Media:
BMC Communications
Susan Duffy, 646-513-3119
sduffy@bmccommunications.com

NephroGenex, Inc.